{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marino C"],"funding":["Ministero dell&apos;Istruzione, dell&apos;Università e della Ricerca","Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)"],"pagination":["108"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12923832"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Schizophrenia is a severe psychiatric disorder that affects approximately 1% of the population. Despite the availability of antipsychotic therapies, about 30% of patients develop treatment-resistant schizophrenia (TRS), defined by a lack of response to at least two different antipsychotic trials. Although several genetic and environmental factors have been proposed to explain treatment resistance, metabolomic studies investigating circulating metabolites in TRS remain limited. In this pilot cross-sectional study, we conducted untargeted <sup>1</sup>H NMR-based metabolomics to profile serum metabolites in TRS versus non-TRS patients. Notably, multivariate analysis revealed distinct serum metabolome profiles between the two groups. Additionally, Variable Importance in Projection (VIP) analys"],"journal":["Translational psychiatry"],"pubmed_title":["Untargeted &lt;sup&gt;1&lt;/sup&gt;H NMR-based metabolomics unveils distinct circulating biochemical signatures between treatment-resistant and non-treatment-resistant schizophrenia patients: a pilot study."],"pmcid":["PMC12923832"],"funding_grant_id":["PE0000006","2017M42834","P2022ZEMZF","2020K53E57"],"pubmed_authors":["Iasevoli F","Errico F","De Simone G","Marino C","Usiello A","Di Maio A","Zhang S","D'Ursi AM","Grimaldi M","de Bartolomeis A"],"additional_accession":[]},"is_claimable":false,"name":"Untargeted &lt;sup&gt;1&lt;/sup&gt;H NMR-based metabolomics unveils distinct circulating biochemical signatures between treatment-resistant and non-treatment-resistant schizophrenia patients: a pilot study.","description":"Schizophrenia is a severe psychiatric disorder that affects approximately 1% of the population. Despite the availability of antipsychotic therapies, about 30% of patients develop treatment-resistant schizophrenia (TRS), defined by a lack of response to at least two different antipsychotic trials. Although several genetic and environmental factors have been proposed to explain treatment resistance, metabolomic studies investigating circulating metabolites in TRS remain limited. In this pilot cross-sectional study, we conducted untargeted <sup>1</sup>H NMR-based metabolomics to profile serum metabolites in TRS versus non-TRS patients. Notably, multivariate analysis revealed distinct serum metabolome profiles between the two groups. Additionally, Variable Importance in Projection (VIP) analys","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T14:48:51.259Z","creation":"2026-07-09T11:02:37.978Z"},"accession":"S-EPMC12923832","cross_references":{"pubmed":["41629277"],"doi":["10.1038/s41398-026-03853-6"]}}